IVVD Stock Overview A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Invivyd, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Invivyd Historical stock prices Current Share Price US$0.44 52 Week High US$5.20 52 Week Low US$0.40 Beta 0.53 1 Month Change -36.71% 3 Month Change -63.01% 1 Year Change -88.56% 3 Year Change -94.87% 5 Year Change n/a Change since IPO -97.87%
Recent News & Updates
Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors Dec 03
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers Nov 13 Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 Oct 30
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants Oct 29
Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data Oct 02 Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19 See more updates
Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors Dec 03
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers Nov 13 Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 Oct 30
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants Oct 29
Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data Oct 02 Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial Aug 27
Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation Jul 16
Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies Jun 02 Invivyd, Inc. Announces Management Changes
Invivyd, Inc. Elects Two New Independent Members to its Board of Directors May 23
Forecast to breakeven in 2026 May 16
Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback May 09
Invivyd, Inc., Annual General Meeting, May 21, 2024 Apr 20
Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda Apr 17
Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda Apr 16 Invivyd, Inc. Announces CEO Changes
Invivyd, Inc. Announces CEO Transition Apr 12
New minor risk - Profitability Apr 11
No longer forecast to breakeven Apr 11
Consensus revenue estimates fall by 13% Apr 07
Invivyd, Inc. Provides Earnings Guidance for the Year 2024 Apr 05
Forecast breakeven date moved forward to 2025 Apr 05
Invivyd, Inc. Provides Earnings Guidance for the Year 2024 Apr 05
Consensus revenue estimates increase by 64% Apr 04
Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth? Mar 29 Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
New minor risk - Shareholder dilution Feb 12
Forecast to breakeven in 2026 Jan 19
Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Dec 24 Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Dec 23
Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 Dec 18
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate Oct 24
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Sep 12
Invivyd, Inc. Appoints William Duke as Chief Financial Officer Sep 06
Invivyd, Inc. Appoints Sara Cotter to Board of Directors Jul 29
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate Jul 04
Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222 Jun 23
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely? Mar 19
Invivyd, Inc. Announces Executive Changes Feb 04
Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc Feb 01
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer Dec 07
Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans? Nov 19
Less than half of directors are independent Nov 16
Invivyd Announces Board Changes Oct 25 Invivyd, Inc. Announces Executive Changes
Invivyd appoints interim CFO, makes headcount changes Oct 13
Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants Sep 13
Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies Sep 12
Adagio Therapeutics GAAP EPS of -$0.47 Aug 15
We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate Jul 30 Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer
Less than half of directors are independent Jul 05
Adagio names David Hering as permanent CEO and Director Jul 05
Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors Jul 02 Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index Adagio Therapeutics, Inc. Elects Class I Directors
Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022 Jun 23 Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022
No longer forecast to breakeven Apr 27
Mithril Capital Provides Information to Shareholders of Adagio Therapeutics Apr 27
Adagio Therapeutics, Inc. Provides Update on Timing of Adintrevimab EUA Request Apr 17
No longer forecast to breakeven Apr 16
No longer forecast to breakeven Mar 31 Mithril Capital Management Communicates with Adagio Therapeutics
Adagio Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2022 Mar 03
Adagio's Round Trip Mar 02
Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates Feb 24
Adagio Therapeutics, Inc. Announces Executive Changes Feb 19
We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow Feb 19
Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention Feb 16
Adagio Therapeutics, Inc. Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron Jan 13
Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate Nov 29
Adagio Therapeutics, Inc. Reports Updates on Its Lead Covid-19 Antibody Program, ADG20 Sep 21
Adagio Therapeutics, Inc. Announces the Independent Data Monitoring Committee (IDMC) for the EVADE Phase 2/3 Trial of ADG20 for the Prevention of COVID-19 Sep 11
Adagio Therapeutics, Inc. has completed an IPO in the amount of $309.4 million. Aug 07 Shareholder Returns IVVD US Biotechs US Market 7D -18.8% -3.6% -2.4% 1Y -88.6% -2.6% 23.4%
See full shareholder returns
Return vs Industry: IVVD underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: IVVD underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is IVVD's price volatile compared to industry and market? IVVD volatility IVVD Average Weekly Movement 14.9% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: IVVD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IVVD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Show more Invivyd, Inc. Fundamentals Summary How do Invivyd's earnings and revenue compare to its market cap? IVVD fundamental statistics Market cap US$53.10m Earnings (TTM ) -US$225.14m Revenue (TTM ) US$11.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IVVD income statement (TTM ) Revenue US$11.56m Cost of Revenue US$894.00k Gross Profit US$10.67m Other Expenses US$235.81m Earnings -US$225.14m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.88 Gross Margin 92.27% Net Profit Margin -1,946.87% Debt/Equity Ratio 0%
How did IVVD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 02:38 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Invivyd, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Kolbert D. Boral Capital LLC. Patrick Trucchio H.C. Wainwright & Co. Michael Yee Jefferies LLC
Show 3 more analysts 
